When was Complete Omics founded?

Complete Omics was founded in 2018 and raised its 1st funding round 5 years after it was founded.

Where is Complete Omics located?

Complete Omics is headquartered in Glen Burnie, United States.

Who is the current CEO of Complete Omics?

Qing Wang of Complete Omics. They have also founded 1 company.

How many employees does Complete Omics have?

As of May 31, 2026, the latest employee count at Complete Omics is 14.

Is Complete Omics a funded company?

Complete Omics is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Nov 14, 2023.

When was the latest funding round of Complete Omics?

Complete Omics' latest funding was a $***** Series A round on Nov 14, 2023, with participation from 1 investor.

Where does Complete Omics rank among its competitors?

Complete Omics ranks 201st amongst 944 active competitors, of which 92 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was IMU Biosciences, which secured an undisclosed amount in Jun, 2026.

Who are the top competitors of Complete Omics?

Complete Omics' top competitors include Cellworks, Alloy Therapeutics and Maiva Pharma. Among them, IMU Biosciences secured the most recent funding round in June, 2026.

Complete Omics - 2026 Company Profile, Team, Funding & Competitors

Complete Omics is a series A company based in Glen Burnie (United States), founded in 2018 by Qing Wang. It operates as a Provider of multi-omics services for biomarker profiling and cancer diagnostics. Complete Omics has raised an undisclosed amount in funding from Qiming Venture Partners. The company has 944 active competitors, including 92 funded and 55 that have exited. Its top competitors include companies like Cellworks, Alloy Therapeutics and Maiva Pharma.

Company Details

Provider of multi-omics services for biomarker profiling and cancer diagnostics. They offer platforms for genomics, proteomics, metabolomics, and single-cell omics. Services include next-generation sequencing, quantitative proteomics, targeted metabolomics, and single-cell RNA sequencing. The company develops clinical multi-omics technologies for personalized neoantigen therapeutic target detection and quantification.

Website: www.completeomics.com/
Social

Key Metrics

Founded Year

2018

Location

Glen Burnie, United States

Stage

Series A

Latest Funding Round

Series A, Nov 14, 2023, $*****

Investors

Qiming Venture Partners

Ranked

201^st among 944 active competitors

Employee Count

14 as on May 31, 2026

Similar Companies

Cellworks & 153 more

View Complete Omics' full profile

Complete Omics has raised funding over 1 round. Its latest funding round was a Series A round on Nov 14, 2023 for $*****. 1 investor participated in its latest round. Complete Omics has 1 institutional investor.

Here is the list of recent funding rounds of Complete Omics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 14, 2023	1905544	Series A	9908258	7463406	9117454	2882743

Access funding benchmarks and valuations. Sign up today!

View details of Complete Omics's funding rounds and investors

The founders of Complete Omics is Qing Wang. Qing Wang is the CEO of Complete Omics.

Here are the details of Complete Omics' key team members:

Qing Wang: Founder & CEO of Complete Omics.
Contact Info: 1 email address

View details of Complete Omics's Founder profiles and Board Members

Complete Omics' employee count trend

Complete Omics has 14 employees as of May 26. Here is Complete Omics's employee count trend over the years:

Uncover Complete Omics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Complete Omics include Cellworks, Alloy Therapeutics and Maiva Pharma. Here is the list of Top 10 competitors of Complete Omics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cellworks 2005, San Jose (United States), Series B	Developer of a biosimulation platform	$16.5M	C-CAMP, Sequoia Capital & 3 others	65/100
2nd	Alloy Therapeutics 2017, Lexington (United States), Series E	Provider of drug discovery services	$157M	8VC, Mubadala & 11 others	63/100
3rd	Maiva Pharma 1996, Hosur (India), Late Stage	Manufacturer of sterile injectables	$125M	Nhpea V Spear, Nano-Vista & 25 others	61/100
4th	Simulations Plus 1996, Lancaster (United States), Public	Developer of modeling and simulation software and consulting services provider	-	NIH, HHS & 1 others	60/100
5th	Manifold Bio 2018, United States, Series A	Developer of tissue-targeted therapeutics using in vivo screening and AI design	$78.2M	Playground Global, Triatomic & 8 others	58/100
6th	Life Bit 2017, London (United Kingdom), Series B	AI and SaaS-based genomics analysis software for drug development	$70.9M	Tiger Global Management, Pentech & 13 others	56/100
7th	ICarbonX 2015, Shenzhen (China), Series D	Provider of bioinformatic platforms for health management and drug development	$366M	Wealthking Investments, Tencent & 11 others	55/100
8th	IMU Biosciences 2019, London (United Kingdom), Series A	Provider of immune discovery platform for precision medicines	$53M	Molten Ventures, IQ Capital & 4 others	55/100
9th	VelaVigo 2021, Shanghai (China), Seed	Biotechnology research company developing biological drugs	$160M	Shunwei Capital, Panacea Venture & 17 others	54/100
10th	Biostate 2023, Houston (United States), Series A	Developer of generative AI based RNAstate research platform to predict future omics states	$16M	Accel, Gaingels & 9 others	54/100
201st	Complete Omics 2018, Glen Burnie (United States), Series A	Provider of multi-omics services for biomarker profiling and cancer diagnostics	-	Qiming Venture Partners	25/100